Wegovy
Wegovy® is a prescription-only weight loss injection containing semaglutide, a medicine that mimics a natural hormone called GLP-1. It helps regulate appetite and food intake by:
-
Increasing feelings of fullness
-
Reducing hunger and cravings
-
Slowing digestion so you stay satisfied longer
It’s taken once a week using a pre-filled pen and is approved in the UK for adults living with obesity or overweight.
We use the same UK pharmaceutical wholesalers that also supply medicines to the NHS. This guarantees your injections follow a secure and safe supply chain.
Eligibility
We may prescribe Mounjaro or Wegovy alongside a reduced-calorie diet and increased physical activity to support weight loss and long-term weight management. These treatments are suitable for adults aged 18 to 85 who meet the following criteria:
A body mass index (BMI) of 30 kg/m² or greater (obesity) or:
A BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) and weight-related health problems such as:
-
Pre-diabetes
-
High blood pressure
-
Abnormal levels of fats in the blood
-
Obstructive sleep apnoea
-
History of heart attack, stroke or blood vessel problems
We are unable to offer weight loss injections for diabetic patients as your overall management is best maintained by your diabetic team.
You should not take Wegovy if:
-
You have severe problems with food digestion or food remaining in your stomach for longer than normal (including severe gastroparesis).
-
You have ever had pancreatitis (inflammation of the pancreas which may cause severe pain in the stomach and back, which does not go away).
-
You have a problem with your eyes (diabetic retinopathy or macular oedema).
-
You are using a sulphonylurea (diabetes medicine) or insulin, as low blood sugar (hypoglycaemia) can occur. Your healthcare professional may need to change your dose of these other medicines to reduce this risk.
-
You have hepatic (liver) or renal (kidney) impairment.
-
You have been diagnosed with an eating disorder.
How effective is Wegovy
By week 68 patients on Wegovy can achieve an average weight loss of 15% on a maintenance dose.
1 in 3 patients achieved ≥20% weight loss at 2 years, in addition to a reduced-calorie diet and increased physical activity. That’s why we offer free coaching—to help patients stay motivated, make sustainable changes, and get the most out of their treatment.
Wegovy® N=1306, placebo N=655, mean baseline body weight Wegovy® = 105.4 kg, mean baseline body weight placebo = 105.2 kg Based on the STEP 1 trial. 14.9% weight loss (~15%) with Wegovy® is based on the treatment estimand. The treatment estimand policy statement evaluates the treatment effect of Wegovy® as placebo regardless of treatment discontinuation or rescue intervention; 16.9% weight loss (~17%) is for the trial product estimand. The trial product estimand evaluates treatment effect if trial product was taken as intended (i.e. all participants adhered to treatment and did not receive rescue intervention). The ≥20% threshold was not part of the statistical testing hierarchy.
Cardiovascular Protection
-
It’s now approved not only for weight management, but also for reducing the risk of serious cardiovascular events in patients with established heart disease.
-
Wegovy helps reduce the risk of major cardiovascular events—such as heart attack, stroke, or cardiovascular death—by 20% compared to placebo, when used alongside standard care and healthy lifestyle changes.
-
This benefit was observed in adults with a BMI of 27 or higher and a history of heart disease, over an average follow-up of nearly 40 months.
Joint Pain Relief with Weight Loss
-
In adults with obesity and moderate knee osteoarthritis, Wegovy showed clinically meaningful improvements in knee pain and delivered superior weight loss versus placebo over 68 weeks, when paired with a reduced-calorie diet and increased physical activity.
Higher Wegovy dose
-
A new 7.2 mg dose is currently pending approval for market release. Clinical data shows an average weight loss of 21%, with 1 in 3 patients achieving ≥ 25% reduction.
20% relative risk reduction (1.5% ARR) in MACE (composite of CV death, non-fatal heart attack and non-fatal stroke) vs placebo, in addition to standard of care, in adult patients with established CVD and BMI ≥27 kg/m², over a mean follow-up of 3.9 months. Primary composite endpoint (predefined): Time to first occurrence of a three-part composite outcome, MACE, which included CV death, non-fatal MI, or non-fatal stroke. All patients were treated on top of standard of care, which included management of CV risk factors including medical treatment in accordance with treatment guidelines or local clinical practice and healthy lifestyle counselling (including reduced-calorie diet and increased physical activity). In the SELECT trial, established cardiovascular disease was defined as prior myocardial infarction, prior stroke or symptomatic peripheral arterial disease. SELECT trial: N=8038, placebo N=4030; active N=4008; the patients had no diabetes.
Get your full guide
-
Understanding more about living with excess weight or obesity
-
Losing weight and keeping it off can be challenging
-
How does Wegovy® work?
-
Get to know your Wegovy® FlexTouch® pen
-
How to use once-weekly Wegovy® Video
-
Stepping up your dose
-
Missed doses, storage and disposal
-
Wegovy® safety information
-
Most common side effects
-
Serious side effects
-
Eating a balanced diet
-
Tips for being more active
-
Monitoring my weight loss journey
Managing potential side effects
Like all medicines, Wegovy can cause side effects, although not everyone gets them. The most common side effects, which may affect more than 1 in 10 people, include:
-
Feeling sick (nausea). Most common when first starting Wegovy but then improves for most patients
-
Diarrhoea
-
Being sick (vomiting)
-
Constipation
-
Feeling weak or tired
-
Stomach pain
These side effects are most common when first starting Wegovy and usually improve over time. Our clinicians will guide you.
If you experience nausea then these tips can help:
-
Eat smaller meals. E.g. split your 3 main meals into 4 or more smaller meals in a day
-
Stop eating when you feel full
-
Avoid food with high fat content
-
Eating bland foods like toast, crackers, or rice
Wegovy Delivery
Wegovy requires cold storage during transit. Once you receive your item please store in the refrigerator between 2°C to 8°C. Do not freeze. Your injectable pen will be packaged in WoolCool insulation & ice packs to help maintain the correct temperature during transit.
Once your start using the Wegovy pen it can be stored at room temperature up to 30° for 6 weeks.
Free home delivery. You will receive by recorded delivery hence someone must be home to sign for your package.
Track your delivery with our partnering courier. Once delivery is made we can not take responsibility for missing parcels and will not be able to offer a refund.
Wegovy comes with its own needles. You will receive alcohol wipes with each order.
